OncoSec reports net loss of $6.5 million for fourth quarter of fiscal 2015
OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the fourth quarter and fiscal year ended July 31, 2015.